Kingsley Leung, CFA

Kingsley Leung, CFA has a long history of work experience. Starting in 2007, they worked as a Private Wealth Management Summer Analyst for Goldman Sachs. In 2008, they moved to Merrill Lynch as a Healthcare Investment Banking Analyst. In 2010, they became an Investment Analyst for Synergy Investment Management Group Limited. From 2011 to 2014, they worked as a Business Development Manager for ASLAN Pharmaceuticals. In 2017, they became an Investment Principal for Jade Ark Capital Limited. In 2018, they were a Non Executive Director for DotBio. In 2019, they were appointed Chairman and Co-Founder of Great Bay Bio and Chairman of Uni-Bio Science Group Limited.

Kingsley Leung, CFA has an extensive education history. Kingsley obtained their BSc in Biochemistry from Imperial College London between 2005 and 2008 and their MSc in Pharmacology from the University of Oxford between 2008 and 2009. In 2010, they obtained their HSK Level 9 from the Ministry of Education of the People's Republic of China. In 2013, they became a Chartered Financial Analyst (CFA) charterholder from the CFA Institute. In 2015, they obtained their Professional Diploma in Corporate Governance & Directorship from The Hong Kong Institute of Directors. Finally, between 2017 and 2019, they obtained their Executive MBA, Tsinghua-INSEAD Executive MBA (TIEMBA), with a field of study in Business Administration and Management, General, from both INSEAD and Tsinghua University.